Jenner Institute, University of Oxford on the Potential of a Cancer Vaccine

Professor Adrian Hill discusses the development of cancer vaccines using adenoviral vectors, building on the success of COVID-19 vaccines. The focus is on prostate and lung cancer, with trials underway. The discussion includes a comparison of adenoviral and mRNA technologies, the future of cancer vaccines, and innovative immunization approaches. The potential for faster vaccine development post-COVID-19 and the impact of public perception on clinical trials are also explored.

What is the significance of the chimpanzee adenoviral vector in vaccine development?

How does the use of mRNA vaccines compare to the adenoviral vector approach?

What lessons have been learned from the COVID-19 pandemic regarding vaccine development timelines?

What future developments in cancer vaccines does Professor Hill foresee?